<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5529019</article-id><article-id pub-id-type="pmid">28708900</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0005757</article-id><article-id pub-id-type="publisher-id">PNTD-D-17-00314</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject><subj-group><subject>Andes Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject><subj-group><subject>Andes Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject><subj-group><subject>Andes Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject><subj-group><subject>Andes Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Bunyaviruses</subject><subj-group><subject>Hantavirus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>South America</subject><subj-group><subject>Chile (Country)</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Headaches</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Serum levels of interleukin-6 are linked to the severity of the disease caused by Andes Virus</article-title><alt-title alt-title-type="running-head">IL-6 and the severity of HCPS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Angulo</surname><given-names>Jenniffer</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Valdebenito</surname><given-names>Constanza</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marco</surname><given-names>Claudia</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Galeno</surname><given-names>H&#x000e9;ctor</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villagra</surname><given-names>Eliecer</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vera</surname><given-names>Lilian</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lagos</surname><given-names>Natalia</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Becerra</surname><given-names>Natalia</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mora</surname><given-names>Judith</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Berm&#x000fa;dez</surname><given-names>Andrea</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>D&#x000ed;az</surname><given-names>Janepsy</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Project administration</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferr&#x000e9;s</surname><given-names>Marcela</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7936-8478</contrib-id><name><surname>L&#x000f3;pez-Lastra</surname><given-names>Marcelo</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Laboratorio de Virolog&#x000ed;a Molecular, Instituto Milenio de Inmunolog&#x000ed;a e Inmunoterapia (IMII), Departamento de Enfermedades Infecciosas e Inmunolog&#x000ed;a Pedi&#x000e1;trica, Divisi&#x000f3;n de Pediatr&#x000ed;a, Escuela de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile, Santiago, Chile</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Laboratorio de Infectolog&#x000ed;a, Departamento de Enfermedades Infecciosas e Inmunolog&#x000ed;a Pedi&#x000e1;trica, Divisi&#x000f3;n de Pediatr&#x000ed;a, Escuela de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile, Santiago, Chile</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Subdepartamento de Virolog&#x000ed;a Cl&#x000ed;nica, Departamento Laboratorio Biom&#x000e9;dico Nacional y de Referencia, Instituto de Salud P&#x000fa;blica de Chile, Santiago, Chile</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Departamento de Asuntos Cient&#x000ed;ficos, Instituto de Salud P&#x000fa;blica de Chile, Santiago, Chile</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Aguilar</surname><given-names>Patricia V.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Texas Medical Branch, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>malopez@med.puc.cl</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><volume>11</volume><issue>7</issue><elocation-id>e0005757</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Angulo et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Angulo et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pntd.0005757.pdf"/><abstract><p>Andes virus (ANDV) is the etiological agent of hantavirus cardiopulmonary syndrome in Chile. In this study, we evaluated the profile of the pro-inflammatory cytokines IL-1&#x003b2;, IL-12p70, IL-21, TNF-&#x003b1;, IFN-&#x003b3;, IL-10 and IL-6 in serum samples of ANDV-infected patients at the time of hospitalization. The mean levels of circulating cytokines were determined by a Bead-Based Multiplex assay coupled with Luminex detection technology, in order to compare 43 serum samples of healthy controls and 43 samples of ANDV-infected patients that had been categorized according to the severity of disease. When compared to the controls, no significant differences in IL-1&#x003b2; concentration were observed in ANDV-infected patients (p = 0.9672), whereas levels of IL-12p70 and IL-21 were significantly lower in infected cases (p = &#x0003c;0.0001). Significantly elevated levels of TNF-&#x003b1;, IFN-&#x003b3;, IL-10, and IL-6 were detected in ANDV-infected individuals (p = &#x0003c;0.0001, 0.0036, &#x0003c;0.0001, &#x0003c;0.0001, respectively). Notably, IL-6 levels were significantly higher (40-fold) in the 22 patients with severe symptoms compared to the 21 individuals with mild symptoms (p = &#x0003c;0.0001). Using multivariate regression models, we show that IL-6 levels has a crude OR of 14.4 (CI: 3.3&#x02013;63.1). In conclusion, the serum level of IL-6 is a significant predictor of the severity of the clinical outcome of ANDV-induced disease.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Andes virus (ANDV) causes hantavirus cardiopulmonary syndrome (HCPS) that is characterized by the development of vascular leakage syndrome, eventually leading to massive pulmonary edema, shock and, in many cases, death. To date, no FDA-approved immunotherapeutics, specific antivirals, or vaccines are available for use against HCPS. Patient survival rates hinge largely on early virus diagnosis, hospital admission and aggressive pulmonary and hemodynamic support in an intensive care unit. Individual host factors associated with the outcome of an ANDV infection are poorly known, and such knowledge could allow the disease progression of hospitalized patients to be predicted, resulting in individualized treatment. In this study, we show that serum levels of IL-6 at the time of hospitalization in ANDV-infected patients are associated with the severity of the clinical outcome of ANDV-induced disease. Therefore, these finding suggest that determining IL-6 levels at the time of admission to the hospital could be useful to predict the progression of ANDV-induced disease.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica de Chile</institution></funding-source><award-id>CONICYT PIA ACT1408</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7936-8478</contrib-id><name><surname>L&#x000f3;pez-Lastra</surname><given-names>Marcelo</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Fondo Nacional de Desarrollo Cient&#x000ed;fico y Tecnol&#x000f3;gico de Chile.</institution></funding-source><award-id>FONDECYT 1161197</award-id><principal-award-recipient><name><surname>Ferr&#x000e9;s</surname><given-names>Marcela</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Iniciativa Cient&#x000ed;fica Milenio del Ministerio de Econom&#x000ed;a, Fomento y Turismo</institution></funding-source><award-id>Proyecto P09/016-F, Instituto Milenio de Inmunolog&#x000ed;a e Inmunoterapia.</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7936-8478</contrib-id><name><surname>L&#x000f3;pez-Lastra</surname><given-names>Marcelo</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica de Chile</institution></funding-source><award-id>CONICYT PIA ACT1408 Post-Doctoral Fellowship</award-id><principal-award-recipient><name><surname>Angulo</surname><given-names>Jenniffer</given-names></name></principal-award-recipient></award-group><funding-statement>The study was funded by the Comisi&#x000f3;n Nacional de Investigaci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica de Chile (CONICYT) [<ext-link ext-link-type="uri" xlink:href="http://www.conicyt.cl/">http://www.conicyt.cl/</ext-link>] through grants CONICYT PIA ACT1408 and FONDECYT 1161197, and the Iniciativa Cient&#x000ed;fica Milenio [<ext-link ext-link-type="uri" xlink:href="http://www.iniciativamilenio.cl/">http://www.iniciativamilenio.cl/</ext-link>] del Ministerio de Econom&#x000ed;a, Fomento y Turismo [Proyecto P09/016-F, Instituto Milenio de Inmunolog&#x000ed;a e Inmunoterapia, IMII]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="5"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2017-07-26</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Andes virus (ANDV) is a rodent-borne hantavirus member of the <italic>Bunyaviridae</italic> family, and is unique for its ability to be transmitted from person-to-person [<xref rid="pntd.0005757.ref001" ref-type="bibr">1</xref>,<xref rid="pntd.0005757.ref002" ref-type="bibr">2</xref>]. ANDV is endemic in Chile and according to the Chilean Ministry of Health (Department of Epidemiology, Chilean Ministry of Health; <ext-link ext-link-type="uri" xlink:href="http://www.minsal.cl/">http://www.minsal.cl</ext-link>), 1087 cases of ANDV infection have been confirmed through May 2017 with a lethality rate of 35&#x02013;40%. In humans, ANDV infection causes hantavirus cardiopulmonary syndrome (HCPS) [<xref rid="pntd.0005757.ref003" ref-type="bibr">3</xref>,<xref rid="pntd.0005757.ref004" ref-type="bibr">4</xref>]. The initial symptoms of HCPS are non-specific and include fever, headache, and myalgia among others. However, in later phases, symptoms progress from coughing to severe pulmonary edema requiring intubation and mechanical ventilation, whilst cardiogenic shock is the main cause of death [<xref rid="pntd.0005757.ref003" ref-type="bibr">3</xref>,<xref rid="pntd.0005757.ref004" ref-type="bibr">4</xref>]. Like other hantaviruses, the ANDV-induced illness is associated with the activation of the host's innate immune response, with cytokines playing a key role, rather than with direct cellular destruction induced by active virus replication [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>]. Currently, no FDA approved drugs, immunotherapeutics, or vaccines are available for HCPS prevention or treatment [<xref rid="pntd.0005757.ref006" ref-type="bibr">6</xref>]. Thus, patients&#x02019; survival rates hinge largely on early diagnosis, hospital admission and aggressive pulmonary and hemodynamic support in an intensive care unit [<xref rid="pntd.0005757.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0005757.ref008" ref-type="bibr">8</xref>]. Moreover, there are no blood biomarkers to predict the outcome of ANDV-induced HCPS. Interestingly, several reports show that the levels of the pro-inflammatory cytokines TNF-&#x003b1;, IL-1, IL-6, IL-10, and IFN-&#x003b3; increase in patients infected with other hantaviruses such as Puumala Virus (PUUV), Dobrava Virus (DOBV), or the Sin Nombre Virus (SNV) [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref009" ref-type="bibr">9</xref>,<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0005757.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0005757.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005757.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0005757.ref015" ref-type="bibr">15</xref>]. Additionally, high levels of IL-6 and TNF-&#x003b1; in plasma of SNV- and PUUV-infected patients is associated with a severe or fatal disease outcome [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005757.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0005757.ref016" ref-type="bibr">16</xref>]. In the case of ANDV, elevated levels of cytokines including IL-6 were reported in ANDV-infected air-exposed organotypic human lung tissues [<xref rid="pntd.0005757.ref017" ref-type="bibr">17</xref>]. Motivated by these findings, we designed a study to evaluate the cytokine profile (IL-1&#x003b2;, IL-12p70, IL-21, TNF-&#x003b1;, IFN-&#x003b3;, IL-10, IL-6) in serum samples of Chilean ANDV-infected patients collected at the time of hospitalization with the aim of establishing if the levels of any of the selected cytokines are linked to the severity of ANDV-induced disease. Cytokine selection was based on reports published for ANDV and other hantaviruses [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005757.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0005757.ref016" ref-type="bibr">16</xref>]. Three cohorts were included; a group of healthy controls, a cohort of ANDV-infected patients with mild disease progression, and a cohort of ANDV-infected patients with a severe disease progression, many of whom subsequently died. Results show that on admission to hospital TNF-&#x003b1;, IFN-&#x003b3;, IL-10, and IL-6 levels were elevated in serum of ANDV-infected patients compared to controls. Importantly, the serum levels of IL-6 in ANDV-infected patients at the time of hospitalization were associated with the severity of the clinical outcome of ANDV-induced disease.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Study population</title><p>A total of 43 non-heat inactivated serum samples from ANDV-infected patients were selected based on their availability. Samples were obtained from a collection generated between January 2006 and January 2014 and stored at the Instituto de Salud P&#x000fa;blica (ISP) de Chile or at the Laboratorio de Infectolog&#x000ed;a, Facultad de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile. These samples were collected for ANDV diagnosis at the time the patient was admitted to hospital, equivalent to 2&#x02013;11 days after suspected ANDV infection (prodromic stage of the clinical course of HCPS). After collection, samples were stored at -8&#x000b0;C and not thawed more than once before use. In a previous study, the samples used had been catalogued as coming from patients with mild or severe symptoms, according to the severity of the final outcome of the ANDV-induced disease [<xref rid="pntd.0005757.ref018" ref-type="bibr">18</xref>]. Selected patients were non-related individuals and were considered to be representative of each group. Mild hantavirus infection was characterized by a febrile illness with unspecific symptoms such as headache, myalgias, chills, gastrointestinal symptoms, and no or minimal respiratory compromise [<xref rid="pntd.0005757.ref018" ref-type="bibr">18</xref>]. Severe cases exhibited rapid and progressive impaired lung function with the need for an external oxygen supply and the use of vasoactive drugs, resulting in shock and/or death [<xref rid="pntd.0005757.ref018" ref-type="bibr">18</xref>]. Based on this categorization, of the 43 infected samples used in this study, 21 were from mild casesand 22 were from severe cases. Fourteen individuals from the latter group subsequently died of HCPS, whilst there were no fatalities in the group showing mild symptoms. Approval for the use of the samples in this study was obtained from the Ethical Review Board of the Facultad de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile (code 12&#x02013;292 and 14&#x02013;438). ANDV infection was confirmed by positive hantavirus immunoglobulin (IgM) serology or by ANDV genome detection by reverse transcription polymerase chain reaction (RT-PCR) [<xref rid="pntd.0005757.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0005757.ref019" ref-type="bibr">19</xref>,<xref rid="pntd.0005757.ref020" ref-type="bibr">20</xref>]. Control samples correspond to 43 non-heat treated serum samples obtained from healthy donors, who tested negative for ANDV, the human immunodeficiency virus, and hepatitis B and C virus infection.</p></sec><sec id="sec004"><title>Determination of cytokine levels in serum samples</title><p>Cytokines IL-1&#x003b2;, IL-12p70, IL-21, TNF-&#x003b1;, IFN-&#x003b3;, IL-10 and IL-6 were measured in serum samples using a custom made Milliplex magnetic bead panel (Merck KGaA, Darmstadt, Germany) following the manufacturer&#x02019;s instructions. The lower limit of detection (pg/mL) for each cytokine in the assay was: IL-1&#x003b2;, 2.5; IL-12p70, 1.84; IL-21, 2.37; TNF- &#x003b1;, 1.23; IFN-&#x003b3;, 4.95; IL-10, 4.5 and IL-6, 3.34.</p></sec><sec id="sec005"><title>Statistical analysis</title><p>Results were analyzed using Graph Prism V6.0 (La Jolla, CA, USA) and Statistical Package for the Social Sciences (SPSS) V10.1 (SPSS, Inc., Chicago, IL, USA) software. The significance between the clinical and laboratory findings variables, and the clinical outcome was calculated by a Fisher`s exact test. The relationship between the clinical outcome and the cytokine levels was determined by a Mann-Whitney test for continuous variables using only two variables in each analysis. The crude odd ratio (OR) values were calculated by a univariate logistic regression analysis followed by a multivariate stepwise forward and reverse logistic regression analysis using SPSS V10.1 software package. P values of &#x0003c;0.05 were considered as significant.</p></sec></sec><sec sec-type="results" id="sec006"><title>Results</title><p>The general characteristics of the ANDV-infected patients included in the study are summarized in <xref ref-type="table" rid="pntd.0005757.t001">Table 1</xref>. The mean age of the patients was 33 &#x000b1; 14 years and 60.5% were male (<xref ref-type="table" rid="pntd.0005757.t001">Table 1</xref>). The vast majority of patients (97.7%) were infected between 32&#x000b0; 02&#x02019; and 56&#x000b0; 30&#x02019; south latitude (in the center and south of Chile) in rural areas (92.5%), consistent with the geographical distribution of the known viral reservoir in the long-tailed pygmy rice rat (<italic>Oligoryzomys longicaudatus</italic>) [<xref rid="pntd.0005757.ref021" ref-type="bibr">21</xref>]. The main clinical features and laboratory findings of the ANDV-infected patients, at the time of their admission in a hospital care unit are summarized in <xref ref-type="table" rid="pntd.0005757.t002">Table 2</xref>. In a previous study, samples of ANDV-infected patients used in this study had been grouped into mild or severe cases depending on the final clinical outcome of the disease [<xref rid="pntd.0005757.ref018" ref-type="bibr">18</xref>] (<xref ref-type="table" rid="pntd.0005757.t001">Table 1</xref>). A univariante analysis revealed that respiratory distress and haematocrit levels at the time of sample collection were significantly higher in patients that ultimately exhibited a severe clinical outcome (<xref ref-type="table" rid="pntd.0005757.t002">Table 2</xref>).</p><table-wrap id="pntd.0005757.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.t001</object-id><label>Table 1</label><caption><title>Characteristic of andes virus-infected patients (n = 43).</title></caption><alternatives><graphic id="pntd.0005757.t001g" xlink:href="pntd.0005757.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Patients, No. (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="justify" rowspan="1" colspan="1">Male [n (%)]</td><td align="left" rowspan="1" colspan="1">26 (60.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female [n (%)]</td><td align="left" rowspan="1" colspan="1">17 (39.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age (mean, &#x000b1; SD)</bold></td><td align="left" rowspan="1" colspan="1">33 &#x000b1;14</td></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;15 [n (%)]</td><td align="left" rowspan="1" colspan="1">3 (7.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">16&#x02013;30 [n (%)]</td><td align="left" rowspan="1" colspan="1">15 (34.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">31&#x02013;50 [n (%)]</td><td align="left" rowspan="1" colspan="1">19 (44.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">51&#x02013;80 [n (%)]</td><td align="left" rowspan="1" colspan="1">6 (14.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Area (South latitude)</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">North (17&#x000ba;30&#x02019; to 32&#x000ba;16&#x02019;) [n (%)]</td><td align="left" rowspan="1" colspan="1">1 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Center (32&#x000ba;02&#x02019;to 36&#x000ba;33&#x02019;) [n (%)]</td><td align="left" rowspan="1" colspan="1">8 (18.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">South (36&#x000ba;00&#x02019; to 56&#x000ba;30&#x02019;) [n (%)]</td><td align="left" rowspan="1" colspan="1">34 (79.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Area of infection [n (%)]<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urban area</td><td align="left" rowspan="1" colspan="1">3 (7.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rural area</td><td align="left" rowspan="1" colspan="1">37 (92.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Outcome</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mild [n (%)]</td><td align="left" rowspan="1" colspan="1">21 (48.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe [n (%)]<xref ref-type="table-fn" rid="t001fn003"><sup>b</sup></xref></td><td align="left" rowspan="1" colspan="1">22 (51.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total Lethality [n (%)]</td><td align="left" rowspan="1" colspan="1">14 (32.5)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviation: SD, Standard deviation.</p></fn><fn id="t001fn002"><p><sup>a</sup> 40 patients with available data.</p></fn><fn id="t001fn003"><p><sup>b</sup> Including the 14 deceased patients.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd.0005757.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.t002</object-id><label>Table 2</label><caption><title>Available clinical and laboratory findings at the time of sample collection.</title></caption><alternatives><graphic id="pntd.0005757.t002g" xlink:href="pntd.0005757.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variable</th><th align="center" colspan="2" rowspan="1">Patients, No. (%)</th><th align="center" rowspan="2" colspan="1">P value</th></tr><tr><th align="center" rowspan="1" colspan="1">Severe<break/>Disease<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">Mild<break/>Disease<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Fever (&#x0003e;38.5&#x000b0;C)</bold></td><td align="center" rowspan="1" colspan="1">22 (100.0)</td><td align="center" rowspan="1" colspan="1">19 (90.5)</td><td align="center" rowspan="1" colspan="1">0.2326</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gastrointestinal symptoms</bold></td><td align="center" rowspan="1" colspan="1">16 (72.7)</td><td align="center" rowspan="1" colspan="1">16 (76.2)</td><td align="center" rowspan="1" colspan="1">0.5360</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Headache</bold></td><td align="center" rowspan="1" colspan="1">20 (90.9)</td><td align="center" rowspan="1" colspan="1">18 (85.7)</td><td align="center" rowspan="1" colspan="1">0.4771</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Myalgia</bold></td><td align="center" rowspan="1" colspan="1">18 (81.8)</td><td align="center" rowspan="1" colspan="1">18 (85.7)</td><td align="center" rowspan="1" colspan="1">0.5274</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Respiratory distress</bold></td><td align="center" rowspan="1" colspan="1">22 (100.0)</td><td align="center" rowspan="1" colspan="1">12 (57.1)</td><td align="center" rowspan="1" colspan="1">***0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Infiltrates on chest X-ray</bold></td><td align="center" rowspan="1" colspan="1">19 (86.4)</td><td align="center" rowspan="1" colspan="1">15 (71.4)</td><td align="center" rowspan="1" colspan="1">0.2043</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Blood shift (&#x0003e;10% bands)</bold></td><td align="center" rowspan="1" colspan="1">6 (27.3)</td><td align="center" rowspan="1" colspan="1">2 (9.5)</td><td align="center" rowspan="1" colspan="1">0.1350</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Atypical lymphocytosis</bold><xref ref-type="table-fn" rid="t002fn002"><sup><bold>b</bold></sup></xref></td><td align="center" rowspan="1" colspan="1">2 (10.5)<xref ref-type="table-fn" rid="t002fn003"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">1 (4.8)</td><td align="center" rowspan="1" colspan="1">0.4615</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Thrombocytopenia</bold><xref ref-type="table-fn" rid="t002fn004"><sup><bold>d</bold></sup></xref></td><td align="center" rowspan="1" colspan="1">19 (86.4)</td><td align="center" rowspan="1" colspan="1">19 (90.5)</td><td align="center" rowspan="1" colspan="1">0.5229</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Increased hematocrit</bold><xref ref-type="table-fn" rid="t002fn005"><sup><bold>e</bold></sup></xref></td><td align="center" rowspan="1" colspan="1">12 (54.5)</td><td align="center" rowspan="1" colspan="1">5 (23.8)</td><td align="center" rowspan="1" colspan="1">*0.0394</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a</sup> Classified according to clinical outcome.</p></fn><fn id="t002fn002"><p><sup>b</sup> Defined as &#x0003e;10% atypical lymphocytes.</p></fn><fn id="t002fn003"><p><sup>c</sup> Available data for 19 severe patients.</p></fn><fn id="t002fn004"><p><sup>d</sup> Defined as &#x0003c; 150.000 mm<sup>3</sup>.</p></fn><fn id="t002fn005"><p><sup>e</sup> Defined as &#x0003e;52% for men and &#x0003e;48% for women.</p></fn></table-wrap-foot></table-wrap><sec id="sec007"><title>Cytokine levels in serum of healthy controls and ANDV-infected patients</title><p>The levels of pro-inflammatory cytokines in serum samples of healthy controls and ANDV-infected patients were determined using a custom designed Th17 based Bead-Based Multiplex assay coupled with a Luminex platform. The results obtained for IL-1&#x003b2;, IL-12p70, IL-21, TNF-&#x003b1;, IFN-&#x003b3;, IL-10, and IL-6 in each group are shown in Figs <xref ref-type="fig" rid="pntd.0005757.g001">1</xref> and <xref ref-type="fig" rid="pntd.0005757.g002">2</xref>, whilst the mean concentration (pg/mL) of each cytokine is shown in <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>. When compared to the group of non-infected controls, no significant differences in IL-1&#x003b2; concentration were observed in ANDV-infected patients (mild plus severe patients; p = 0.9672), when comparing the control group with each individual sub-group (mild p: 0.5916; severe p = 0.6549), or between those suffering mild or severe symptoms (p = 0.4759) (<xref ref-type="fig" rid="pntd.0005757.g001">Fig 1A</xref> and <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>). The levels of IL-12p70 and IL-21 were significantly lower in ANDV-infected patients when compared to the controls (p = &#x0003c;0.0001), although no differences in the levels of IL-12p70 (p = 0.4119) and IL-21 (p = 0.9084) were detected between those showing mild and severe symptoms (<xref ref-type="fig" rid="pntd.0005757.g001">Fig 1B and 1C</xref>, and <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>). The expression of TNF-&#x003b1; (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2A</xref>), IFN-&#x003b3; (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2B</xref>), IL-10 (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2C</xref>), and IL-6 (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2D</xref>) exhibited higher levels in ANDV-infected individuals than in the non-infected control group, and levels were not affected by disease severity in the case of TNF-&#x003b1;, IFN-&#x003b3;, and IL-10 (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2A&#x02013;2C</xref> and <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>). Notably however, the severe group of ANDV-infected patients displayed significantly more IL-6 compared to those with milder disease symptoms (2.1 log<sub>10</sub>, fold increase of 40.4; p &#x0003c;0.0001) (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2D</xref> and <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>). Due to the evident overlap in the levels of IL-6 when patients are categorized as mild or severe, it may be that reliance on IL-6 to determine a "severe" outcome for a patient is inadequate. To address this issue, the 43 patients were grouped according to their real final status, as either survivors or fatalities (<xref ref-type="fig" rid="pntd.0005757.g003">Fig 3</xref> and <xref ref-type="table" rid="pntd.0005757.t004">Table 4</xref>). For this, the eight severe patients who survived were grouped with the 21 mild individuals (none of whom died), and these 29 patients were then compared with the 14 severe and fatal cases of ANDV infection. The results show that the serum concentration of IL-6 was significantly higher in the fatal cases compared to the surviving (2.0 log<sub>10</sub>, fold increase of 28.3; p &#x0003c;0.0001) or the control group (3.2 log<sub>10</sub>, fold increase 150.8; p &#x0003c;0.0001) (<xref ref-type="fig" rid="pntd.0005757.g003">Fig 3</xref> and <xref ref-type="table" rid="pntd.0005757.t004">Table 4</xref>).</p><fig id="pntd.0005757.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.g001</object-id><label>Fig 1</label><caption><title>IL-1&#x003b2;, IL-12p70, and IL-21 levels in control and ANDV-infected patients.</title><p>Circulating levels of cytokines (A) IL-1&#x003b2;, (B) IL-12p70 and (C) IL-21 in serum samples of Control individuals and ANDV-infected patients with Mild or Severe disease progression are represented by dots. IL-1&#x003b2; and IL-12p70 were expressed in pg/mL while the circulating levels of IL-21 are expressed as Log<sub>10</sub> (pg/mL) to facilitate comparison between the groups. A Mann-Whitney test for continuous variables was performed to evaluate significant differences between Controls and Mild or Severe, and Severe versus Mild groups. The ends of the brackets indicate the compared groups. The dashed line represents the lower limit of detection. Each serum sample was analyzed in duplicate in the same plate.</p></caption><graphic xlink:href="pntd.0005757.g001"/></fig><fig id="pntd.0005757.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.g002</object-id><label>Fig 2</label><caption><title>TNF-&#x003b1;, IFN-&#x003b3;, IL-10, and IL-6 levels in control and ANDV-infected patients.</title><p>Circulating levels of cytokines (A) TNF-&#x003b1;, (B) IFN-&#x003b3;, (C) IL-10, and (D) IL-6 in serum samples of Control individuals and ANDV-infected patients with Mild or Severe disease progression are represented by dots. Each value expressed in pg/mL was transformed to Log<sub>10</sub> (pg/mL) to facilitate comparison between the groups. A Mann-Whitney test for continuous variables was performed to evaluate significant differences between Controls and Mild or Severe, and Severe versus Mild groups. The dashed line represents the lower limit of detection. The ends of the brackets indicate the compared groups. Each serum sample was analyzed in duplicate in the same plate.</p></caption><graphic xlink:href="pntd.0005757.g002"/></fig><fig id="pntd.0005757.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.g003</object-id><label>Fig 3</label><caption><title>Serum levels of IL-6 in control, HCPS survivals or fatal cases.</title><p>Circulating levels of IL-6 in serum samples of control individuals and HCPS survivors or fatalities are represented by dots. Values are expressed in Log<sub>10</sub> (pg/mL). A Mann-Whitney test for continuous variables was performed to evaluate significant differences between controls individuals and HCPS survivors or fatalities. The ends of the brackets indicate the compared groups. The dashed line represents the lower limit of detection. Each serum sample was analyzed in duplicate in the same plate.</p></caption><graphic xlink:href="pntd.0005757.g003"/></fig><table-wrap id="pntd.0005757.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.t003</object-id><label>Table 3</label><caption><title>Cytokine concentration in serum of controls and ANDV-infected patients.</title></caption><alternatives><graphic id="pntd.0005757.t003g" xlink:href="pntd.0005757.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"><break/>Cytokine</th><th align="center" rowspan="2" colspan="1"><break/>Controls<break/>[mean (min-max) pg/mL]<break/>(n = 43)</th><th align="center" colspan="3" rowspan="1">ANDV-Infected Patients<break/>[mean (min-max) pg/mL]</th></tr><tr><th align="center" rowspan="1" colspan="1">Total<break/>(n = 43)</th><th align="center" rowspan="1" colspan="1">Mild Disease<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref><break/>(n = 21)</th><th align="center" rowspan="1" colspan="1">Severe Disease<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref><break/>(n = 22)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>IL-1&#x003b2;</bold></td><td align="left" rowspan="1" colspan="1">3.49 (2.5&#x02013;33.94)</td><td align="left" rowspan="1" colspan="1">4.60 (2.5&#x02013;64.62)</td><td align="left" rowspan="1" colspan="1">3.84 (2.5&#x02013;26.06)</td><td align="left" rowspan="1" colspan="1">5.32 (2.5&#x02013;64.62)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>IL-12p70</bold></td><td align="left" rowspan="1" colspan="1">21.86 (1.84&#x02013;104.31)</td><td align="left" rowspan="1" colspan="1">5.43 (1.84&#x02013;51.26)</td><td align="left" rowspan="1" colspan="1">7.28 (1.84&#x02013;51.26)</td><td align="left" rowspan="1" colspan="1">3.67 (1.84&#x02013;27.88)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>IL-21</bold></td><td align="left" rowspan="1" colspan="1">74.23 (2.37&#x02013;303.0)</td><td align="left" rowspan="1" colspan="1">16.75 (2.37&#x02013;186.5)</td><td align="left" rowspan="1" colspan="1">21.57 (2.37&#x02013;186.5)</td><td align="left" rowspan="1" colspan="1">12.14 (2.37&#x02013;119.5)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TNF-&#x003b1;</bold></td><td align="left" rowspan="1" colspan="1">21.55 (2.90&#x02013;85.35)</td><td align="left" rowspan="1" colspan="1">70.05 (15.87&#x02013;407)</td><td align="left" rowspan="1" colspan="1">61.01 (17.18&#x02013;144.5)</td><td align="left" rowspan="1" colspan="1">78.68 (15.87&#x02013;407)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>IFN-</bold>&#x003b3;</td><td align="left" rowspan="1" colspan="1">31.38 (4.95&#x02013;183.0)</td><td align="left" rowspan="1" colspan="1">69.62 (4.95&#x02013;652.0)</td><td align="left" rowspan="1" colspan="1">50.21 (4.95&#x02013;183.0)</td><td align="left" rowspan="1" colspan="1">88.13 (5.99&#x02013;652.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>IL-10</bold></td><td align="left" rowspan="1" colspan="1">5.74 (4.5&#x02013;45.49)</td><td align="left" rowspan="1" colspan="1">133.21 (4.5&#x02013;776.0)</td><td align="left" rowspan="1" colspan="1">129.85 (4.5&#x02013;776.0)</td><td align="left" rowspan="1" colspan="1">136.25 (4.5&#x02013;347.0)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>IL-6</bold></td><td align="left" rowspan="1" colspan="1">7.84 (3.34&#x02013;105.64)</td><td align="left" rowspan="1" colspan="1">411.94 (3.34&#x02013;10281.8)</td><td align="left" rowspan="1" colspan="1">19.47 (3.34&#x02013;75.66)</td><td align="left" rowspan="1" colspan="1">786.57 (3.34&#x02013;10281.8)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><sup>a</sup> Classified according to clinical outcome.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pntd.0005757.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.t004</object-id><label>Table 4</label><caption><title>Cytokine concentration in serum of survivors or deceased ANDV-infected patients.</title></caption><alternatives><graphic id="pntd.0005757.t004g" xlink:href="pntd.0005757.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"><break/>Cytokine</th><th align="center" colspan="3" rowspan="1">ANDV-Infected Patients<break/>[mean (min-max) pg/mL]</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="center" rowspan="1" colspan="1">Total<break/>(n = 43)</th><th align="center" rowspan="1" colspan="1">Survivals<xref ref-type="table-fn" rid="t004fn001"><sup>a</sup></xref><break/>(n = 29)</th><th align="center" rowspan="1" colspan="1">Fatal cases<xref ref-type="table-fn" rid="t004fn001"><sup>a</sup></xref><break/>(n = 14)</th><th align="center" rowspan="1" colspan="1">P value<break/>(Mann-Whitney test)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>IL-1&#x003b2;</bold></td><td align="center" rowspan="1" colspan="1">4.60 (2.5&#x02013;64.62)</td><td align="center" rowspan="1" colspan="1">3.48 (2.5&#x02013;26.06)</td><td align="center" rowspan="1" colspan="1">6.94 (2.5&#x02013;64.62)</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.9999</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-12p70</bold></td><td align="center" rowspan="1" colspan="1">5.43 (1.84&#x02013;51.26)</td><td align="center" rowspan="1" colspan="1">5.96 (1.84&#x02013;51.26)</td><td align="center" rowspan="1" colspan="1">4.35 (1.84&#x02013;27.88)</td><td align="center" rowspan="1" colspan="1">0.7508</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-21</bold></td><td align="center" rowspan="1" colspan="1">16.75 (2.37&#x02013;186.5)</td><td align="center" rowspan="1" colspan="1">17.36 (2.37&#x02013;186.5)</td><td align="center" rowspan="1" colspan="1">15.48 (2.37&#x02013;119.5)</td><td align="center" rowspan="1" colspan="1">0.5314</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>TNF-&#x003b1;</bold></td><td align="center" rowspan="1" colspan="1">70.05 (15.87&#x02013;407)</td><td align="center" rowspan="1" colspan="1">61.75 (17.18&#x02013;144.5)</td><td align="center" rowspan="1" colspan="1">87.26 (15.87&#x02013;407)</td><td align="center" rowspan="1" colspan="1">0.6521</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IFN-&#x003b3;</bold></td><td align="center" rowspan="1" colspan="1">69.62 (4.95&#x02013;652.0)</td><td align="center" rowspan="1" colspan="1">81.85 (4.95&#x02013;652)</td><td align="center" rowspan="1" colspan="1">44.27 (5.99&#x02013;93.57)</td><td align="center" rowspan="1" colspan="1">0.8880</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-10</bold></td><td align="center" rowspan="1" colspan="1">133.21 (4.5&#x02013;776.0)</td><td align="center" rowspan="1" colspan="1">128.40 (4.5&#x02013;776.0)</td><td align="center" rowspan="1" colspan="1">143.22 (4.5&#x02013;347.0)</td><td align="center" rowspan="1" colspan="1">0.3618</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-6</bold></td><td align="center" rowspan="1" colspan="1">411.94 (3.34&#x02013;10281.8)</td><td align="center" rowspan="1" colspan="1">41.59 (3.34&#x02013;285)</td><td align="center" rowspan="1" colspan="1">1179.08 (13.075&#x02013;10281.8)</td><td align="center" rowspan="1" colspan="1">**** &#x0003c;0.0001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p><sup>a</sup> Classified according to clinical outcome.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec008"><title>Risk factor analysis by using a logistic regression model</title><p>To control the potential confounding effects of the various risk factors identified by the univariate analysis, a multiple logistic regression model was constructed using the outcome and symptom severity of ANDV-infection, as the response variables. The stepwise forward and reverse logistic regression analysis included clinical variables (fever, gastrointestinal symptoms, headache, myalgia, respiratory distress, infiltrates on chest x-ray, blood shift, atypical lymphocytosis, thrombocytopenia, increased hematocrit) and the cytokine profiles. All cytokine values were dichotomized (above or under mean values). <xref ref-type="table" rid="pntd.0005757.t005">Table 5</xref> summarizes the crude odd ratios (OR) for each variable processed by a univariate logistic regression model, and the OR obtained by a multivariate stepwise forward (model 1) and reverse (model 2) logistic regression analysis. In model 1, respiratory distress (p = 0.9999) and IL-6 (p = 0.0130) are the only variables that affect HCPS outcome. In model 2, respiratory distress (p = 0.9999), increased hematocrit (p = 0.0670), and IL-6 (p = 0.0150) impact on HCPS outcome. However, for both models, only the difference between the levels of IL-6 in mild and severe ANDV-infected patients is significant, with OR values greater than 1.</p><table-wrap id="pntd.0005757.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005757.t005</object-id><label>Table 5</label><caption><title>Logistic regression of clinical and cytokine level variables.</title></caption><alternatives><graphic id="pntd.0005757.t005g" xlink:href="pntd.0005757.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><break/>Variable</th><th align="center" rowspan="1" colspan="1"><break/>crude OR</th><th align="center" rowspan="1" colspan="1"><break/>CI<sub>or</sub></th><th align="center" rowspan="1" colspan="1">OR<sub>model 1</sub><break/>(IL-6 and respiratory distress)</th><th align="center" rowspan="1" colspan="1"><break/>CI<sub>or</sub></th><th align="center" rowspan="1" colspan="1">OR<sub>model 2</sub><break/>(IL-6, respiratory distress and increased hematocrit)</th><th align="center" rowspan="1" colspan="1"><break/>CI<sub>or</sub></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><bold>Fever <xref ref-type="table-fn" rid="t005fn001"><sup>a</sup></xref></bold></td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Gastrointestinal symptoms</bold></td><td align="center" rowspan="1" colspan="1">1.2</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;4.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Headache</bold></td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;4.1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Myalgia</bold></td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;6.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Respiratory distress <xref ref-type="table-fn" rid="t005fn001"><sup>a</sup></xref></bold></td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">1.0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Infiltrate on chest X-Ray</bold></td><td align="center" rowspan="1" colspan="1">0.4</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;1.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Blood shift</bold></td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;1.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Atypical lymphocytosis</bold></td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">0.2&#x02013;26</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Thrombocytopenia</bold></td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">0.2&#x02013;10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>Increased hematocrit</bold><xref ref-type="table-fn" rid="t005fn002">*</xref></td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">1&#x02013;14.2</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.9</td><td align="center" rowspan="1" colspan="1">0.8&#x02013;54.9</td></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-1&#x003b2;</bold></td><td align="center" rowspan="1" colspan="1">0.4</td><td align="center" rowspan="1" colspan="1">0.4&#x02013;5.4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-12p70</bold></td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">0.3&#x02013;3.0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-21</bold></td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;2.4</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>TNF-&#x003b1;</bold></td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">0.5&#x02013;5.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IFN-&#x003b3;</bold></td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">0.4&#x02013;4.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-10</bold></td><td align="center" rowspan="1" colspan="1">2.0</td><td align="center" rowspan="1" colspan="1">0.6&#x02013;6.9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"><bold>IL-6</bold><xref ref-type="table-fn" rid="t005fn002">*</xref></td><td align="center" rowspan="1" colspan="1">14.4</td><td align="center" rowspan="1" colspan="1">3.3&#x02013;63.1</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">1.6&#x02013;74.7</td><td align="center" rowspan="1" colspan="1">10.9</td><td align="center" rowspan="1" colspan="1">1.6&#x02013;74.7</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p><sup>a</sup> OR not calculated because one or more boxes contain zero.</p></fn><fn id="t005fn002"><p><sub>*</sub> Significant</p></fn><fn id="t005fn003"><p>OR model 1: Stepwise Forward</p></fn><fn id="t005fn004"><p>OR model 2: Stepwise Reverse</p></fn></table-wrap-foot></table-wrap><p>In summary, the results from this study show that IL-6 serum concentration at the time of patient hospitalization is linked to the severity of the disease induced by ANDV.</p></sec></sec><sec sec-type="conclusions" id="sec009"><title>Discussion</title><p>A growing number of reports suggest that the hosts&#x02019; immune response plays a key role in hantavirus induced disease [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref009" ref-type="bibr">9</xref>,<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0005757.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0005757.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005757.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0005757.ref015" ref-type="bibr">15</xref>,<xref rid="pntd.0005757.ref022" ref-type="bibr">22</xref>]. Studies indicate that immune dysregulation rather than virus replication is responsible for the increasing changes in vascular permeability associated with HCPS [<xref rid="pntd.0005757.ref023" ref-type="bibr">23</xref>,<xref rid="pntd.0005757.ref024" ref-type="bibr">24</xref>]. Upon hantavirus infection, the pathogens-associated molecular patterns (PAMPs) are recognized by the extracellular or intracellular receptors of endothelial host cells, leading to the local production of pro-inflammatory cytokines and chemokines, such as IL-1&#x003b2;, TNF-&#x003b1;, and IL-6, by activated macrophages [<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref025" ref-type="bibr">25</xref>,<xref rid="pntd.0005757.ref026" ref-type="bibr">26</xref>]. Additionally, Th1 cells produce IFN-&#x003b3; and TGF-&#x003b2;, cytokines that are responsible for cell-mediated immunity, regulated by IL-12 [<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref027" ref-type="bibr">27</xref>]. The regulatory T cells that produce the immunosuppressive cytokines IL-10 and TGF-&#x003b2; play an important role in the regulation of the immune response and limit the immunopathology induced by hantavirus infection [<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>]. Thus, we were interested in determining whether the levels of serum cytokines in patients at the time of their admission to hospital were associated with the final clinical outcome of the ANDV-induced disease. To do so, we compared the levels of serum cytokines in three distinct groups of individuals: non-infected individuals (healthy controls), ANDV-infected patients with a mild disease progression and ANDV-infected patients with a severe disease progression.</p><p>When studying IL-1&#x003b2; we found that the serum levels of this cytokine remain unaltered in ANDV-infected patients when compared to that of the non-infected controls (<xref ref-type="fig" rid="pntd.0005757.g001">Fig 1A</xref>). This finding confirms previous reports showing no increase in the levels of IL-1&#x003b2; in patients infected with PUUV or in patients with HCPS [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>]. Nonetheless, other studies show that the cells producing IL-1&#x003b2; and other pro-inflammatory cytokines are concentrated in the lung tissue of individuals with HCPS [<xref rid="pntd.0005757.ref026" ref-type="bibr">26</xref>,<xref rid="pntd.0005757.ref028" ref-type="bibr">28</xref>]. Therefore, these observations suggest that production of local cytokines in the lungs of ANDV-infected patients could differ from circulating levels of cytokines.</p><p>Results regarding the levels of IL-21 in hantavirus-infected individuals are dissimilar between previous reports [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref029" ref-type="bibr">29</xref>]. One study shows a high overexpression of IL-21 in patients with hemorrhagic fever with renal syndrome (HFRS) caused by hantavirus [<xref rid="pntd.0005757.ref029" ref-type="bibr">29</xref>]. In that study, the authors establish an association between the levels of IL-21 and the severity of HFRS. However, another study reports that there is no change in the levels of IL-21 in the serum of HCPS patients [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>]. In contrast to both previous studies [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref029" ref-type="bibr">29</xref>], our results show that in the group of ANDV-infected patients, IL-21 levels are significantly lower when compared to non-infected controls (p = &#x0003c;0.0001) (<xref ref-type="fig" rid="pntd.0005757.g001">Fig 1C</xref>). It is worth noting that the pathology induced by New-World hantaviruses, HCPS, shares many, although not all of the clinical features of the disease caused by Old-World hantaviruses, HFRS. Thus, results obtained in the context of ANDV infection are not expected to fully match those that have been described for Old-World hantaviruses.</p><p>An interesting, yet expected finding, is that in ANDV-infected patients the serum levels of IL-12p70 are significantly lower (p = &#x0003c;0.0001) when compared to the non-infected control group. This observation is in full agreement with a study showing a similar trend in Dobrava virus (DOBV) infected patients [<xref rid="pntd.0005757.ref015" ref-type="bibr">15</xref>]. A plausible explanation is to consider that the overexpression of a repressor cytokine, such as IL-10, would down regulate the levels of IL-12p70 [<xref rid="pntd.0005757.ref030" ref-type="bibr">30</xref>]. This possibility is strongly supported by our results, in which the level of IL-10 in serum of ANDV-infected patients is significantly higher (p = &#x0003c;0.0001) than in the healthy controls (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2C</xref>; <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>). It is well known that the overexpression of IL-10 is strongly favored by high levels of IL-6 and TNF-&#x003b1; [<xref rid="pntd.0005757.ref015" ref-type="bibr">15</xref>]. Additionally, overexpression of TNF-&#x003b1; and IL-6 are associated with inflammatory systemic disease, an increase in vascular permeability and with the production of a negative inotropic effect [<xref rid="pntd.0005757.ref031" ref-type="bibr">31</xref>,<xref rid="pntd.0005757.ref032" ref-type="bibr">32</xref>]. In agreement with this positive loop of activation, our results show that the levels of IL-6 and TNF-&#x003b1; are elevated in ANDV-infected patients (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2A and 2D</xref>). In fact, when compared to non-infected controls, significant increases in the levels of TNF-&#x003b1;, IFN-&#x003b3;, IL-10 and IL-6 in ANDV-infected patient are observed (p = &#x0003c;0.0001; 0.0036; &#x0003c;0.0001; &#x0003c;0.0001, respectively) (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2A&#x02013;2D</xref>). These findings are in full agreement with most previous studies [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005757.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0005757.ref015" ref-type="bibr">15</xref>,<xref rid="pntd.0005757.ref033" ref-type="bibr">33</xref>], although TNF-&#x003b1; expression is not always raised in patients with severe HCPS [<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>]. This discrepancy cannot be readily explained; however, one possibility is to consider the genetic differences between the subjects included in these two studies, one conducted in Brazil [<xref rid="pntd.0005757.ref010" ref-type="bibr">10</xref>] and the other in Chile. Differences between both populations have been previously reported in other studies [<xref rid="pntd.0005757.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0005757.ref034" ref-type="bibr">34</xref>].</p><p>Additionally, we compared TNF-&#x003b1;, IL-10, and IL-6 levels between mild and severe cases of ANDV-infection. Even though no significant differences in TNF-&#x003b1; or IL-10 levels exist between these two groups (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2A and 2C</xref>, and <xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref>), the IL-6 levels in the serum of ANDV-infected patients with a mild disease progression increased by 2.49 fold (p = 0.0021) compared to the non-infected controls (<xref ref-type="fig" rid="pntd.0005757.g002">Fig 2D</xref>), whilst those with severe symptoms displayed a 100.7 fold (p = &#x0003c;0.0001) increase in the levels of IL-6 compared to the control group (<xref ref-type="table" rid="pntd.0005757.t003">Table 3</xref> and <xref ref-type="fig" rid="pntd.0005757.g002">Fig 2D</xref>). Moreover, when categorizing patients into survivors and fatalities the IL-6 levels in fatal cases of ANDV infection were significantly higher compared to survivor or control patients (<xref ref-type="fig" rid="pntd.0005757.g003">Fig 3</xref> and <xref ref-type="table" rid="pntd.0005757.t004">Table 4</xref>). Finally, a multivariate stepwise forward and reverse logistic regression model was constructed, confirming the relevance of the IL-6 levels at the time of patient hospitalization in the prediction of the outcome of HCPS (<xref ref-type="table" rid="pntd.0005757.t005">Table 5</xref>). It is well documented that IL-6 levels are significantly elevated in the serum of patients with HCPS, epidemic nephropathy (EP), and HFRS [<xref rid="pntd.0005757.ref005" ref-type="bibr">5</xref>,<xref rid="pntd.0005757.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0005757.ref035" ref-type="bibr">35</xref>]. Consistent with our findings, other reports show that IL-6 levels are even higher in severe-disease patients compared with mild-disease patients [<xref rid="pntd.0005757.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005757.ref035" ref-type="bibr">35</xref>]. Thus, our findings establish a clear association between the Th1-type cytokine IL-6 and the severity of ANDV-induced HCPS, suggesting that the serum concentration of IL-6 at the time of hospitalization can potentially be used as a molecular marker to predict the clinical outcome in ANDV-infected patients, offering the promise of personalized intervention, right from the moment of hospital admission.</p></sec></body><back><ack><p>We thank Dr. Michael Handford, Universidad de Chile, for language support.</p></ack><ref-list><title>References</title><ref id="pntd.0005757.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>VP</given-names></name>, <name><surname>Bellomo</surname><given-names>C</given-names></name>, <name><surname>San Juan</surname><given-names>J</given-names></name>, <name><surname>Pinna</surname><given-names>D</given-names></name>, <name><surname>Forlenza</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Person-to-person transmission of Andes virus</article-title>. <source>Emerg Infect Dis</source>
<volume>11</volume>: <fpage>1848</fpage>&#x02013;<lpage>1853</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3201/eid1112.050501">10.3201/eid1112.050501</ext-link></comment>
<?supplied-pmid 16485469?><pub-id pub-id-type="pmid">16485469</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Padula</surname><given-names>PJ</given-names></name>, <name><surname>Edelstein</surname><given-names>A</given-names></name>, <name><surname>Miguel</surname><given-names>SD</given-names></name>, <name><surname>Lopez</surname><given-names>NM</given-names></name>, <name><surname>Rossi</surname><given-names>CM</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus</article-title>. <source>Virology</source>
<volume>241</volume>: <fpage>323</fpage>&#x02013;<lpage>330</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1006/viro.1997.8976">10.1006/viro.1997.8976</ext-link></comment>
<?supplied-pmid 9499807?><pub-id pub-id-type="pmid">9499807</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Enria</surname><given-names>DA</given-names></name>, <name><surname>Briggiler</surname><given-names>AM</given-names></name>, <name><surname>Pini</surname><given-names>N</given-names></name>, <name><surname>Levis</surname><given-names>S</given-names></name> (<year>2001</year>) <article-title>Clinical manifestations of New World hantaviruses</article-title>. <source>Current topics in microbiology and immunology</source>
<volume>256</volume>: <fpage>117</fpage>&#x02013;<lpage>134</lpage>. <?supplied-pmid 11217400?><pub-id pub-id-type="pmid">11217400</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Figueiredo</surname><given-names>LT</given-names></name>, <name><surname>Souza</surname><given-names>WM</given-names></name>, <name><surname>Ferres</surname><given-names>M</given-names></name>, <name><surname>Enria</surname><given-names>DA</given-names></name> (<year>2014</year>) <article-title>Hantaviruses and cardiopulmonary syndrome in South America</article-title>. <source>Virus Res</source>
<volume>187</volume>: <fpage>43</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.virusres.2014.01.015">10.1016/j.virusres.2014.01.015</ext-link></comment>
<?supplied-pmid 24508343?><pub-id pub-id-type="pmid">24508343</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Morzunov</surname><given-names>SP</given-names></name>, <name><surname>Khaiboullina</surname><given-names>SF</given-names></name>, <name><surname>St Jeor</surname><given-names>S</given-names></name>, <name><surname>Rizvanov</surname><given-names>AA</given-names></name>, <name><surname>Lombardi</surname><given-names>VC</given-names></name> (<year>2015</year>) <article-title>Multiplex Analysis of Serum Cytokines in Humans with Hantavirus Pulmonary Syndrome</article-title>. <source>Frontiers in immunology</source>
<volume>6</volume>: <fpage>432</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2015.00432">10.3389/fimmu.2015.00432</ext-link></comment>
<?supplied-pmid 26379668?><pub-id pub-id-type="pmid">26379668</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Dolgin</surname><given-names>E</given-names></name> (<year>2012</year>) <article-title>Hantavirus treatments advance amidst outbreak in US park</article-title>. <source>Nat Med</source>
<volume>18</volume>: <fpage>1448</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm1012-1448a">10.1038/nm1012-1448a</ext-link></comment>
<?supplied-pmid 23042337?><pub-id pub-id-type="pmid">23042337</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Jonsson</surname><given-names>CB</given-names></name>, <name><surname>Hooper</surname><given-names>J</given-names></name>, <name><surname>Mertz</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Treatment of hantavirus pulmonary syndrome</article-title>. <source>Antiviral Res</source>
<volume>78</volume>: <fpage>162</fpage>&#x02013;<lpage>169</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2007.10.012">10.1016/j.antiviral.2007.10.012</ext-link></comment>
<?supplied-pmid 18093668?><pub-id pub-id-type="pmid">18093668</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Macneil</surname><given-names>A</given-names></name>, <name><surname>Nichol</surname><given-names>ST</given-names></name>, <name><surname>Spiropoulou</surname><given-names>CF</given-names></name> (<year>2011</year>) <article-title>Hantavirus pulmonary syndrome</article-title>. <source>Virus Res</source>
<volume>162</volume>: <fpage>138</fpage>&#x02013;<lpage>147</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.virusres.2011.09.017">10.1016/j.virusres.2011.09.017</ext-link></comment>
<?supplied-pmid 21945215?><pub-id pub-id-type="pmid">21945215</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Bondu</surname><given-names>V</given-names></name>, <name><surname>Schrader</surname><given-names>R</given-names></name>, <name><surname>Gawinowicz</surname><given-names>MA</given-names></name>, <name><surname>McGuire</surname><given-names>P</given-names></name>, <name><surname>Lawrence</surname><given-names>DA</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Elevated cytokines, thrombin and PAI-1 in severe HCPS patients due to Sin Nombre virus</article-title>. <source>Viruses</source>
<volume>7</volume>: <fpage>559</fpage>&#x02013;<lpage>589</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/v7020559">10.3390/v7020559</ext-link></comment>
<?supplied-pmid 25674766?><pub-id pub-id-type="pmid">25674766</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Borges</surname><given-names>AA</given-names></name>, <name><surname>Campos</surname><given-names>GM</given-names></name>, <name><surname>Moreli</surname><given-names>ML</given-names></name>, <name><surname>Moro Souza</surname><given-names>RL</given-names></name>, <name><surname>Saggioro</surname><given-names>FP</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Role of mixed Th1 and Th2 serum cytokines on pathogenesis and prognosis of hantavirus pulmonary syndrome</article-title>. <source>Microbes and infection / Institut Pasteur</source>
<volume>10</volume>: <fpage>1150</fpage>&#x02013;<lpage>1157</lpage>.</mixed-citation></ref><ref id="pntd.0005757.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Kyriakidis</surname><given-names>I</given-names></name>, <name><surname>Papa</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>Serum TNF-alpha, sTNFR1, IL-6, IL-8 and IL-10 levels in hemorrhagic fever with renal syndrome</article-title>. <source>Virus research</source>
<volume>175</volume>: <fpage>91</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.virusres.2013.03.020">10.1016/j.virusres.2013.03.020</ext-link></comment>
<?supplied-pmid 23603136?><pub-id pub-id-type="pmid">23603136</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Linderholm</surname><given-names>M</given-names></name>, <name><surname>Ahlm</surname><given-names>C</given-names></name>, <name><surname>Settergren</surname><given-names>B</given-names></name>, <name><surname>Waage</surname><given-names>A</given-names></name>, <name><surname>Tarnvik</surname><given-names>A</given-names></name> (<year>1996</year>) <article-title>Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome</article-title>. <source>The Journal of infectious diseases</source>
<volume>173</volume>: <fpage>38</fpage>&#x02013;<lpage>43</lpage>. <?supplied-pmid 8537680?><pub-id pub-id-type="pmid">8537680</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Makela</surname><given-names>S</given-names></name>, <name><surname>Mustonen</surname><given-names>J</given-names></name>, <name><surname>Ala-Houhala</surname><given-names>I</given-names></name>, <name><surname>Hurme</surname><given-names>M</given-names></name>, <name><surname>Koivisto</surname><given-names>AM</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis</article-title>. <source>American journal of kidney diseases: the official journal of the National Kidney Foundation</source>
<volume>43</volume>: <fpage>809</fpage>&#x02013;<lpage>816</lpage>.<pub-id pub-id-type="pmid">15112171</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Sadeghi</surname><given-names>M</given-names></name>, <name><surname>Eckerle</surname><given-names>I</given-names></name>, <name><surname>Daniel</surname><given-names>V</given-names></name>, <name><surname>Burkhardt</surname><given-names>U</given-names></name>, <name><surname>Opelz</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Cytokine expression during early and late phase of acute Puumala hantavirus infection</article-title>. <source>BMC immunology</source>
<volume>12</volume>: <fpage>65</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2172-12-65">10.1186/1471-2172-12-65</ext-link></comment>
<?supplied-pmid 22085404?><pub-id pub-id-type="pmid">22085404</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Saksida</surname><given-names>A</given-names></name>, <name><surname>Wraber</surname><given-names>B</given-names></name>, <name><surname>Avsic-Zupanc</surname><given-names>T</given-names></name> (<year>2011</year>) <article-title>Serum levels of inflammatory and regulatory cytokines in patients with hemorrhagic fever with renal syndrome</article-title>. <source>BMC infectious diseases</source>
<volume>11</volume>: <fpage>142</fpage>.<pub-id pub-id-type="pmid">21605369</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Outinen</surname><given-names>TK</given-names></name>, <name><surname>Makela</surname><given-names>SM</given-names></name>, <name><surname>Ala-Houhala</surname><given-names>IO</given-names></name>, <name><surname>Huhtala</surname><given-names>HS</given-names></name>, <name><surname>Hurme</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations</article-title>. <source>BMC infectious diseases</source>
<volume>10</volume>: <fpage>132</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2334-10-132">10.1186/1471-2334-10-132</ext-link></comment>
<?supplied-pmid 20500875?><pub-id pub-id-type="pmid">20500875</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Sundstrom</surname><given-names>KB</given-names></name>, <name><surname>Nguyen Hoang</surname><given-names>AT</given-names></name>, <name><surname>Gupta</surname><given-names>S</given-names></name>, <name><surname>Ahlm</surname><given-names>C</given-names></name>, <name><surname>Svensson</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Andes Hantavirus-Infection of a 3D Human Lung Tissue Model Reveals a Late Peak in Progeny Virus Production Followed by Increased Levels of Proinflammatory Cytokines and VEGF-A</article-title>. <source>PloS one</source>
<volume>11</volume>: <fpage>e0149354</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0149354">10.1371/journal.pone.0149354</ext-link></comment>
<?supplied-pmid 26907493?><pub-id pub-id-type="pmid">26907493</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Angulo</surname><given-names>J</given-names></name>, <name><surname>Pino</surname><given-names>K</given-names></name>, <name><surname>Echeverria-Chagas</surname><given-names>N</given-names></name>, <name><surname>Marco</surname><given-names>C</given-names></name>, <name><surname>Martinez-Valdebenito</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Association of Single-Nucleotide Polymorphisms in IL28B, but Not TNF-alpha, With Severity of Disease Caused by Andes Virus</article-title>. <source>Clinical infectious diseases: an official publication of the Infectious Diseases Society of America</source>
<volume>61</volume>: <fpage>e62</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">26394672</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref019"><label>19</label><mixed-citation publication-type="other">Lee HW, Calisher C, Schmaljohn C, editors (1999) Manual of hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome.</mixed-citation></ref><ref id="pntd.0005757.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Padula</surname><given-names>PJ</given-names></name>, <name><surname>Rossi</surname><given-names>CM</given-names></name>, <name><surname>Della Valle</surname><given-names>MO</given-names></name>, <name><surname>Martinez</surname><given-names>PV</given-names></name>, <name><surname>Colavecchia</surname><given-names>SB</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Development and evaluation of a solid-phase enzyme immunoassay based on Andes hantavirus recombinant nucleoprotein</article-title>. <source>J Med Microbiol</source>
<volume>49</volume>: <fpage>149</fpage>&#x02013;<lpage>155</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1099/0022-1317-49-2-149">10.1099/0022-1317-49-2-149</ext-link></comment>
<?supplied-pmid 10670565?><pub-id pub-id-type="pmid">10670565</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Medina</surname><given-names>RA</given-names></name>, <name><surname>Torres-Perez</surname><given-names>F</given-names></name>, <name><surname>Galeno</surname><given-names>H</given-names></name>, <name><surname>Navarrete</surname><given-names>M</given-names></name>, <name><surname>Vial</surname><given-names>PA</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Ecology, genetic diversity, and phylogeographic structure of andes virus in humans and rodents in Chile</article-title>. <source>J Virol</source>
<volume>83</volume>: <fpage>2446</fpage>&#x02013;<lpage>2459</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.01057-08">10.1128/JVI.01057-08</ext-link></comment>
<?supplied-pmid 19116256?><pub-id pub-id-type="pmid">19116256</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Marsac</surname><given-names>D</given-names></name>, <name><surname>Garcia</surname><given-names>S</given-names></name>, <name><surname>Fournet</surname><given-names>A</given-names></name>, <name><surname>Aguirre</surname><given-names>A</given-names></name>, <name><surname>Pino</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability</article-title>. <source>Virology journal</source>
<volume>8</volume>: <fpage>223</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1743-422X-8-223">10.1186/1743-422X-8-223</ext-link></comment>
<?supplied-pmid 21569520?><pub-id pub-id-type="pmid">21569520</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Khaiboullina</surname><given-names>SF</given-names></name>, <name><surname>Morzunov</surname><given-names>SP</given-names></name>, <name><surname>St Jeor</surname><given-names>SC</given-names></name> (<year>2005</year>) <article-title>Hantaviruses: molecular biology, evolution and pathogenesis</article-title>. <source>Current molecular medicine</source>
<volume>5</volume>: <fpage>773</fpage>&#x02013;<lpage>790</lpage>. <?supplied-pmid 16375712?><pub-id pub-id-type="pmid">16375712</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Maes</surname><given-names>P</given-names></name>, <name><surname>Clement</surname><given-names>J</given-names></name>, <name><surname>Gavrilovskaya</surname><given-names>I</given-names></name>, <name><surname>Van Ranst</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>Hantaviruses: immunology, treatment, and prevention</article-title>. <source>Viral Immunol</source>
<volume>17</volume>: <fpage>481</fpage>&#x02013;<lpage>497</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/vim.2004.17.481">10.1089/vim.2004.17.481</ext-link></comment>
<?supplied-pmid 15671746?><pub-id pub-id-type="pmid">15671746</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Markotic</surname><given-names>A</given-names></name>, <name><surname>Hensley</surname><given-names>L</given-names></name>, <name><surname>Daddario</surname><given-names>K</given-names></name>, <name><surname>Spik</surname><given-names>K</given-names></name>, <name><surname>Anderson</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Pathogenic hantaviruses elicit different immunoreactions in THP-1 cells and primary monocytes and induce differentiation of human monocytes to dendritic-like cells</article-title>. <source>Collegium antropologicum</source>
<volume>31</volume>: <fpage>1159</fpage>&#x02013;<lpage>1167</lpage>. <?supplied-pmid 18217475?><pub-id pub-id-type="pmid">18217475</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>M</given-names></name>, <name><surname>Rothman</surname><given-names>AL</given-names></name>, <name><surname>Kurane</surname><given-names>I</given-names></name>, <name><surname>Montoya</surname><given-names>JM</given-names></name>, <name><surname>Nolte</surname><given-names>KB</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome</article-title>. <source>The Journal of infectious diseases</source>
<volume>179</volume>: <fpage>295</fpage>&#x02013;<lpage>302</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/314597">10.1086/314597</ext-link></comment>
<?supplied-pmid 9878011?><pub-id pub-id-type="pmid">9878011</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>O'Shea</surname><given-names>JJ</given-names></name>, <name><surname>Ma</surname><given-names>A</given-names></name>, <name><surname>Lipsky</surname><given-names>P</given-names></name> (<year>2002</year>) <article-title>Cytokines and autoimmunity</article-title>. <source>Nature reviews Immunology</source>
<volume>2</volume>: <fpage>37</fpage>&#x02013;<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri702">10.1038/nri702</ext-link></comment>
<?supplied-pmid 11905836?><pub-id pub-id-type="pmid">11905836</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Kilpatrick</surname><given-names>ED</given-names></name>, <name><surname>Terajima</surname><given-names>M</given-names></name>, <name><surname>Koster</surname><given-names>FT</given-names></name>, <name><surname>Catalina</surname><given-names>MD</given-names></name>, <name><surname>Cruz</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome</article-title>. <source>Journal of immunology</source>
<volume>172</volume>: <fpage>3297</fpage>&#x02013;<lpage>3304</lpage>.</mixed-citation></ref><ref id="pntd.0005757.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name> (<year>2014</year>) <article-title>Elevated serum IL-21 levels in hantavirus-infected patients correlate with the severity of the disease</article-title>. <source>Inflammation</source>
<volume>37</volume>: <fpage>1078</fpage>&#x02013;<lpage>1083</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10753-014-9831-3">10.1007/s10753-014-9831-3</ext-link></comment>
<?supplied-pmid 24510007?><pub-id pub-id-type="pmid">24510007</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name>, <name><surname>Abrams</surname><given-names>J</given-names></name>, <name><surname>Bennett</surname><given-names>B</given-names></name>, <name><surname>Figdor</surname><given-names>CG</given-names></name>, <name><surname>de Vries</surname><given-names>JE</given-names></name> (<year>1991</year>) <article-title>Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes</article-title>. <source>The Journal of experimental medicine</source>
<volume>174</volume>: <fpage>1209</fpage>&#x02013;<lpage>1220</lpage>. <?supplied-pmid 1940799?><pub-id pub-id-type="pmid">1940799</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Finkel</surname><given-names>MS</given-names></name>, <name><surname>Oddis</surname><given-names>CV</given-names></name>, <name><surname>Jacob</surname><given-names>TD</given-names></name>, <name><surname>Watkins</surname><given-names>SC</given-names></name>, <name><surname>Hattler</surname><given-names>BG</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>Negative inotropic effects of cytokines on the heart mediated by nitric oxide</article-title>. <source>Science</source>
<volume>257</volume>: <fpage>387</fpage>&#x02013;<lpage>389</lpage>. <?supplied-pmid 1631560?><pub-id pub-id-type="pmid">1631560</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Meldrum</surname><given-names>DR</given-names></name> (<year>1998</year>) <article-title>Tumor necrosis factor in the heart</article-title>. <source>The American journal of physiology</source>
<volume>274</volume>: <fpage>R577</fpage>&#x02013;<lpage>595</lpage>. <?supplied-pmid 9530222?><pub-id pub-id-type="pmid">9530222</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Krakauer</surname><given-names>T</given-names></name>, <name><surname>Leduc</surname><given-names>JW</given-names></name>, <name><surname>Krakauer</surname><given-names>H</given-names></name> (<year>1995</year>) <article-title>Serum levels of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome</article-title>. <source>Viral immunology</source>
<volume>8</volume>: <fpage>75</fpage>&#x02013;<lpage>79</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/vim.1995.8.75">10.1089/vim.1995.8.75</ext-link></comment>
<?supplied-pmid 8825292?><pub-id pub-id-type="pmid">8825292</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Borges</surname><given-names>AA</given-names></name>, <name><surname>Donadi</surname><given-names>EA</given-names></name>, <name><surname>Campos</surname><given-names>GM</given-names></name>, <name><surname>Moreli</surname><given-names>ML</given-names></name>, <name><surname>de Sousa</surname><given-names>RL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Association of -308G/A polymorphism in the tumor necrosis factor-alpha gene promoter with susceptibility to development of hantavirus cardiopulmonary syndrome in the Ribeirao Preto region, Brazil</article-title>. <source>Arch Virol</source>
<volume>155</volume>: <fpage>971</fpage>&#x02013;<lpage>975</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00705-010-0655-7">10.1007/s00705-010-0655-7</ext-link></comment>
<?supplied-pmid 20372945?><pub-id pub-id-type="pmid">20372945</pub-id></mixed-citation></ref><ref id="pntd.0005757.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>W</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Yue</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Determination of urine tumor necrosis factor, IL-6, IL-8, and serum IL-6 in patients with hemorrhagic fever with renal syndrome</article-title>. <source>The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases</source>
<volume>16</volume>: <fpage>527</fpage>&#x02013;<lpage>530</lpage>.</mixed-citation></ref></ref-list></back></article>